AIRS Stock Risk & Deep Value Analysis
AirSculpt Technologies Inc
DVR Score
out of 10
What You Need to Know About AIRS Stock
We analyzed AirSculpt Technologies Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran AIRS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
AIRS Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is the company's inability to reverse its declining revenue and case volumes, which could lead to continued net losses, further requiring capital raises through share dilution, ultimately eroding shareholder value and potentially leading to liquidity issues if operational improvements are not realized.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
Low
Red Flags
- ⚠
Year-over-year revenue decline (-14.6% in Q4 2025; -15.8% in FY2025) and case volume decline (-15.0% in Q4 2025).
- ⚠
Widening net loss ($11.7 million in FY2025 from $8.0 million in 2024).
- ⚠
Delayed 10-K filing and amended 8-K for corrected, overstated non-GAAP metrics (Adjusted EBITDA), indicating potential internal control weaknesses.
- ⚠
Share dilution through ATM issuance ($14.8 million raised) during a period of revenue decline and flat guidance.
Upcoming Risk Events
- 📅
Continued decline in revenue and case volumes in future quarters
- 📅
Further dilution through equity raises if cash burn accelerates
- 📅
Increased competitive pressure or inability to differentiate services
When to Reconsider
- 🚪
Exit if quarterly revenue continues to decline YoY beyond Q1 2026 guidance.
- 🚪
Sell if Adjusted EBITDA turns significantly negative or falls below guidance for consecutive quarters.
- 🚪
Re-evaluate if debt-to-equity ratio significantly increases or cash reserves drop below 3 months of operating expenses without a clear funding plan.
Unlock AIRS Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
AirSculpt Technologies represents a deep-value, high-risk turnaround opportunity in the growing elective aesthetic market. The significant insider buying provides a strong signal of conviction. If management can successfully execute on its stated goal of stabilizing revenue (midpoint flat YoY same-store sales for Q1 2026) and improve operational efficiency to achieve its FY2026 Adjusted EBITDA guidance, the stock could experience a substantial re-rating from its currently depressed valuation, leveraging its proprietary technology and direct-to-consumer clinic network.
Is AIRS Stock Undervalued?
Unlock the full AI analysis for AIRS
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
AIRS Price Targets & Strategy
12-Month Target
$6.00
Bull Case
$10.00
Bear Case
$1.50
Valuation Basis
12-month target of $6.00 based on a multiple expansion to 2.5x Price/Sales applied to projected FY2026 revenue of $154M (midpoint of guidance) = $385M market cap, divided by 65M estimated diluted shares.
Entry Strategy
Consider dollar-cost averaging in the $2.00-$2.50 range, near current support levels, to capitalize on potential turnaround signals.
Exit Strategy
Take partial profits at $6.00-$7.00. Re-evaluate holding if it fails to surpass $3.50 within 6-9 months or if a clear downtrend emerges below $2.00. Set a stop loss at $1.80.
Portfolio Allocation
1-3% for aggressive risk tolerance, given the high-risk, turnaround nature.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is AIRS Financially Healthy?
Valuation
P/E Ratio
-4.22
Forward P/E
41.25
EV/EBITDA
9.60
Price/Book
2.03
Price/Sales
0.80
Profitability
Gross Margin
65.95%
Operating Margin
-7.61%
Net Margin
-7.68%
Return on Equity
-13.79%
Revenue Growth
-15.82%
EPS
$-0.19
Balance Sheet
Current Ratio
0.55
Quick Ratio
0.36
Debt/Equity
0.64
Total Debt
$56.00M
Cash & Equivalents
$8.40M
Cash Flow
Operating Cash Flow
-$2.53M
Free Cash Flow
-$3.11M
EBITDA
$15.10M
Other
Beta (Volatility)
2.07
Does AIRS Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Eroding
Moat Sources
3 Identified
The moat relies heavily on brand recognition and the perceived efficacy and safety of its proprietary procedure. It is vulnerable to increasing competition from other aesthetic technologies, shifts in consumer preferences, and potential negative publicity if patient outcomes are unsatisfactory. It could strengthen if the company successfully differentiates and expands its network.
Moat Erosion Risks
- •Increased competition from non-invasive body contouring solutions and other surgical options.
- •Potential for new technologies to render AirSculpt's procedure less appealing or effective.
- •Erosion of brand reputation due to operational missteps or declining patient satisfaction.
AIRS Competitive Moat Analysis
Sign up to see competitive advantages
AIRS Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (no specific data provided, but highly speculative nature suggests mixed retail sentiment)
Institutional Sentiment
Negative (Analyst consensus is 'Reduce' despite a higher median price target)
Insider Activity (Form 4)
Major shareholder Jorey Chernett bought 105,848 shares for $257,210.64 on March 16, 2026. Insiders purchased a total of 690,150 shares worth $1,658,224 in the last 3 months, signaling strong conviction.
Options Flow
Normal options activity (no specific data provided)
Earnings Intelligence
Next Earnings
Estimated early-May 2026 (for Q1 2026, based on Q4 reporting pattern)
Surprise Probability
Medium (beat EPS but missed revenue in Q4 2025; Q1 revenue guidance is flat YoY same-store sales)
Historical Earnings Pattern
Past patterns show mixed results with EPS beats often accompanied by revenue misses, leading to volatile stock reactions.
Key Metrics to Watch
Competitive Position
Top Competitor
InMode Ltd (INMD)
Market Share Trend
Losing ground, evidenced by declining case volumes and revenue.
Valuation vs Peers
Trading at a discount to growth-oriented aesthetic medical device peers (e.g., INMD trades at higher P/E and P/S multiples) due to its revenue declines and unprofitability. AIRS's forward P/S is ~1.17x, significantly lower than profitable growth peers.
Competitive Advantages
- •Proprietary AirSculpt procedure and specialized technology.
- •Direct-to-consumer clinic model with an established brand in its niche.
- •Focus on minimally invasive body contouring with quick recovery times.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive AIRS Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated late April/early May 2026)
- •Evidence of stabilized or returning YoY revenue and case volume growth in Q2 2026
Medium-Term (6-18 months)
- •Successful execution of turnaround strategy leading to sustained profitability
- •Expansion into new geographic markets or service lines (not yet confirmed in research)
- •Significant improvements in operating leverage and margin expansion
Long-Term (18+ months)
- •Establishing market leadership in a niche segment of elective aesthetic procedures
- •Continued brand development and patient loyalty leading to sustained demand
- •Strategic acquisitions to expand clinic footprint or technology offerings
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for AIRS?
- ✓
Consistent positive year-over-year revenue growth (especially same-store sales) starting from H2 2026.
- ✓
Expanding Adjusted EBITDA margins and a clear path to sustained positive free cash flow.
- ✓
Successful integration of new strategic initiatives or expansion plans, if announced.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How AirSculpt Technologies Inc Makes Money
AirSculpt Technologies operates as a direct-to-consumer aesthetic services company, specializing in minimally invasive fat removal and transfer procedures under its proprietary 'AirSculpt' brand. The company performs these body contouring treatments through its network of licensed clinics, where procedures are conducted by board-certified plastic surgeons and dermatologists. The business model emphasizes a premium, personalized patient experience with less downtime compared to traditional liposuction, generating revenue directly from patients for the procedures performed.
Read Full Business Model BreakdownFAQ
What is the DVR Score for AirSculpt Technologies Inc (AIRS)?
As of April 19, 2026, AirSculpt Technologies Inc has a DVR Score of 4.2 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of AirSculpt Technologies Inc?
AirSculpt Technologies Inc's market capitalization is approximately $180.6M..
What is the risk level for AIRS stock?
Our analysis rates AirSculpt Technologies Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of AIRS?
AirSculpt Technologies Inc currently has a price-to-earnings (P/E) ratio of -4.2. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is AirSculpt Technologies Inc's revenue growing?
AirSculpt Technologies Inc has reported revenue growth of -15.8%. Revenue has been declining, which warrants closer examination.
Is AIRS stock profitable?
AirSculpt Technologies Inc has a profit margin of -7.7%. The company is currently unprofitable.
How often is the AIRS DVR analysis updated?
Our AI-powered analysis of AirSculpt Technologies Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 19, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for AIRS (AirSculpt Technologies Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.